US Stock MarketDetailed Quotes
TTOO T2 Biosystems
- 1.3895
- +0.0295+2.17%
Trading Oct 18 14:14 ET
24.29MMarket Cap0.05P/E (TTM)
1.4100High1.3500Low224.51KVolume1.4000Open1.3600Pre Close311.26KTurnover4.38%Turnover RatioLossP/E (Static)17.48MShares8.379952wk High-4.12P/B7.12MFloat Cap1.350052wk Low--Dividend TTM5.12MShs Float122500.0000Historical High--Div YieldTTM4.41%Amplitude1.3500Historical Low1.3860Avg Price1Lot Size
T2 Biosystems Stock Forum
Sign in to post a comment
$T2 Biosystems (TTOO.US)$ T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
1
5
$T2 Biosystems (TTOO.US)$
T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
2
1
$T2 Biosystems (TTOO.US)$ Reuters· 6 mins ago
T2 Biosystems Announces Exclusive U.S. Agreement With Cardinal Health to Sell Its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
T2 Biosystems Announces Exclusive U.S. Agreement With Cardinal Health to Sell Its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
$T2 Biosystems (TTOO.US)$
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
T2 Biosystems (NASDAQ: TTOO) has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH) for the distribution of its FDA-cleared direct-from-blood diagnostics for rapid sepsis detection. The agreement covers the T2Dx® Instrument, T2Bacteria® Panel, and T2Candida® Panel. ...
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
T2 Biosystems (NASDAQ: TTOO) has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH) for the distribution of its FDA-cleared direct-from-blood diagnostics for rapid sepsis detection. The agreement covers the T2Dx® Instrument, T2Bacteria® Panel, and T2Candida® Panel. ...
1
$T2 Biosystems (TTOO.US)$
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results
T2 Biosystems (NASDAQ: TTOO) announced preliminary unaudited financial results for Q3 2024, reporting a 35% increase in total revenue compared to the prior year period. Key highlights include:
- Total revenue of $2.0 million
- Sepsis test panel revenue of $1.6 million, up 42% year-over-year
- Executed contracts for 11 T2Dx® Instruments
- Expanded international distribution to Malaysia and Indon...
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results
T2 Biosystems (NASDAQ: TTOO) announced preliminary unaudited financial results for Q3 2024, reporting a 35% increase in total revenue compared to the prior year period. Key highlights include:
- Total revenue of $2.0 million
- Sepsis test panel revenue of $1.6 million, up 42% year-over-year
- Executed contracts for 11 T2Dx® Instruments
- Expanded international distribution to Malaysia and Indon...
$T2 Biosystems (TTOO.US)$ Reuters· just
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
2
1
$T2 Biosystems (TTOO.US)$
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
T2 Biosystems (NASDAQ:TTOO) has successfully defended a key patent for its direct-from-whole blood detection method in the European Union. The opposition, filed in May 2023 by bioMerieux and an undisclosed party, challenged T2 Biosystems' European Patent No. 3 443 124. This patent is important to the company's intellectual property portfolio...
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
T2 Biosystems (NASDAQ:TTOO) has successfully defended a key patent for its direct-from-whole blood detection method in the European Union. The opposition, filed in May 2023 by bioMerieux and an undisclosed party, challenged T2 Biosystems' European Patent No. 3 443 124. This patent is important to the company's intellectual property portfolio...
$T2 Biosystems (TTOO.US)$ Reuters· 1 min ago
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
1
1
$T2 Biosystems (TTOO.US)$
T2 Biosystems Provides Updates on its New Product Development Pipeline Progress
T2 Biosystems (NASDAQ:TTOO) has provided updates on its new product development pipeline, focusing on direct-from-blood diagnostic tests for antimicrobial resistance, pediatric Candida infections, Lyme disease, and Candida auris. Key highlights include:
1. Finalizing a 510(k) application for the T2Resistance® Panel, planned for Q4 2024 FDA submission.
2. Pending FDA clearance for expande...
T2 Biosystems Provides Updates on its New Product Development Pipeline Progress
T2 Biosystems (NASDAQ:TTOO) has provided updates on its new product development pipeline, focusing on direct-from-blood diagnostic tests for antimicrobial resistance, pediatric Candida infections, Lyme disease, and Candida auris. Key highlights include:
1. Finalizing a 510(k) application for the T2Resistance® Panel, planned for Q4 2024 FDA submission.
2. Pending FDA clearance for expande...
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Papanice9167 : Did you not come in?
Trytosaveabit OP Papanice9167 : No volume yet! Hope it comes? But they burned a lot of people over the last year. So it’s going to take spectacular news IMO to bring that volume back.
NercZ24 Trytosaveabit OP : hmmm?
Salmon Klein Trytosaveabit OP : they burnt to so many people that now no one is interested on this...does not matter what the news will be I won't lose more on this one hahaha
Trytosaveabit OP Salmon Klein : Oh I agree mostly. That’s why I said that! But there is some news that would get people back! If only for a day trade! Hehehe. But like I said. It would have to be stellar news! Hehehe